MedPath

Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer

Not Applicable
Completed
Conditions
Prostatic Diseases
Urological Manifestations
Prostatic Neoplasm
Lower Urinary Tract Symptoms
Interventions
Procedure: Prostatic Artery Embolization
Registration Number
NCT03104907
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization of patients with recurrent symptoms secondary to locally advanced prostatic cancer including pelvic pain, bleeding or need for permanent urinary catheter who are unfit for or refuse surgical treatment.

Detailed Description

This is a prospective study investigating the safety and efficacy of PAE for patients with prostate cancer who suffers from acute urinary retention, severe LUTS and/or recurrent complications such as haematuria.

Our hypothesis is that PAE will eliminate the need for indwelling catheter and improve IPSS and QoL 12 months post-procedure.

1, and 6 months follow-up.

Main outcome Ability to void after removal of indwelling catheter

Secondary outcomes International Prostate Symptom Score (IPSS) Quality of Life (QoL) International Index of Erectile Function (IIEF) Prostate volume Peak void flow (Qmax) Post-void residual (PVR) Classify complications according to Society of Interventional Radiology (SIR) guidelines for reporting Prostate-specific antigen (PSA)

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
15
Inclusion Criteria
  • Indwelling catheter secondary to locally advanced prostate cancer (PCa) or
  • Moderate-severe Obstructive LUTS secondary to PCa
  • Unsuitable for or refuse surgery
Exclusion Criteria
  • Bladder dysfunction(and known neurological conditions affecting bladder function)
  • Urethral strictures
  • Bladder neck contracture
  • Known sphincter anomalies
  • Big bladder diverticulum or stones
  • Kidney insufficiency (eGFR < 45)
  • Coagulation disturbances
  • Severe atheromatous or tortuosity of arteries
  • Allergy to contrast medium
  • Unable to undergo MR imaging
  • Bladder malignancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Prostatic Artery EmbolizationProstatic Artery EmbolizationEmbolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
Primary Outcome Measures
NameTimeMethod
Ability to void spontaneously1 months

The ability to void after removal of the indwelling catheter

Secondary Outcome Measures
NameTimeMethod
QoL1, 6 months

Quality of Life (scale)

PV1, 6 months

Prostate Volume

PVR1, 6 months

Post-void residual

IIEF1, 6 months

International Index of Erectile Function

Qmax1, 6 months

Peak void flow

PSA1, 24-hours, 6 months

Prostate-specific antigen

IPSS1, 6 months

International Prostate Symptom Score

Trial Locations

Locations (1)

Rigshospitalet

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath